Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.

Trial Details

NCT ID
NCT06957431
Phase
PHASE1
Sponsor
Washington University School of Medicine
Status
RECRUITING
Cancer Type
Liposarcoma Sarcoma
Interventions
  • Zanzalintinib
  • Eribulin
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Pathologically proven diagnosis of unresectable or metastatic leiomyosarcoma or adipocytic sarcoma.
  • Progressed on at least 1 line of prior therapy and have received no more than 4 lines of prior therapy.
  • Measurable disease per RECIST 1.1.
  • At least 18 years of age.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →